What is Aadi Bioscience?
Aadi Bioscience operates as a clinical-stage biopharmaceutical entity dedicated to the development of precision medicine for patients diagnosed with genetically-defined cancers. The company's core competency lies in targeting mTOR pathway driver alterations, specifically those involving TSC1 or TSC2 genes. By focusing on these specific molecular targets, Aadi seeks to provide transformational therapeutic options where traditional inhibitors have failed due to limitations in safety, pharmacology, or site-specific targeting. The firm's market position is defined by its commitment to solving complex drug delivery challenges, thereby enhancing the therapeutic index of its lead candidates and improving health-related quality of life for oncology patients.
How much funding has Aadi Bioscience raised?
Aadi Bioscience has raised a total of $195.7M across 4 funding rounds:
Series A
$23M
Debt
$150K
Share Placement
$72.5M
Share Placement
$100M
Series A (2017): $23M with participation from Helsinn Investment Fund, Hermed Capital, Vivo Capital, Celgene Corporation, and Decheng Capital
Debt (2020): $150K led by PPP
Share Placement (2022): $72.5M, investors not publicly disclosed
Share Placement (2025): $100M, investors not publicly disclosed
Key Investors in Aadi Bioscience
Helsinn Investment Fund
A Luxembourg-based investment vehicle focused on early-stage opportunities in high-unmet-need areas, leveraging 40 years of R&D and commercialization expertise in cancer therapeutics.
Hermed Capital
A private investment firm providing flexible working capital solutions, managed by high-net-worth individuals with a focus on specialist financial assets and business growth.
Decheng Capital
A global investment firm specializing in early-stage life science and growth-stage healthcare companies, providing strategic support and capital to build innovative, technology-driven enterprises.
What's next for Aadi Bioscience?
With the recent infusion of capital, Aadi Bioscience is well-positioned to accelerate its clinical development programs and expand its research footprint. The strategic focus will likely shift toward scaling its precision oncology platform and navigating the regulatory pathways required for commercialization. As the company matures, the emphasis will remain on validating its therapeutic candidates through rigorous clinical trials, while simultaneously exploring potential partnerships to enhance its market reach. The current funding environment provides the necessary runway to sustain long-term R&D initiatives, ensuring that Aadi remains at the forefront of innovation in the treatment of mTOR-driven malignancies.
See full Aadi Bioscience company page
